Details:
The Company intends to use the net proceeds from the offering primarily for the acceleration of the development of EscharEx® (bromelain), establishing a U.S. commercial presence, supporting business development activities, and for general corporate purposes.
Lead Product(s): Bromelain
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: EscharXR
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $27.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 07, 2023
Details:
The Company intends to use the net proceeds from the offering primarily for the acceleration of the development of EscharEx. EscharEx, a concentrate of proteolytic enzymes enriched in bromelain, is an easy to use product candidate, for topical daily applications.
Lead Product(s): Bromelain
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: EscharXR
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $27.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 03, 2023
Details:
CM-101 is a first-in-class monoclonal antibody that neutralizes CCL24, a soluble protein with pro-fibrotic and pro-inflammatory effects. It is in development for the treatment of fibro-inflammatory disorders, including primary sclerosingcholangitis and systemic sclerosis.
Lead Product(s): CM-101
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: CM-101
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2022
Details:
The Company intends to use the net proceeds for the development of EscharEx® (bromelain enriched proteolytic enzyme), which has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds and scale up of its facilities.
Lead Product(s): Bromelain Enriched Proteolytic Enzyme
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: EscharEx
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $30.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 07, 2022
Details:
The Company intends to use the net proceeds from the Offerings primarily for the development of EscharEx® (bromelain enriched proteolytic enzyme), a scale up of its facilities, and for general corporate purposes.
Lead Product(s): Bromelain Enriched Proteolytic Enzyme
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: EscharEx
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 22, 2022
Details:
Study met primary endpoint with patients treated with EscharEx (Bromelain Enriched Proteolytic Enzyme) had statistically significant higher incidence of complete debridement during the 14-day measurement period within up to 8 applications compared to gel vehicle.
Lead Product(s): Bromelain Enriched Proteolytic Enzyme
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: EscharEx
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
EscharEx, a concentrate of proteolytic enzymes enriched in bromelain, for debridement of chronic and other hard-to-heal wounds is a product candidate in advanced stages of development.
Lead Product(s): Bromelain Enriched Proteolytic Enzyme
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: EscharEx
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2022
Details:
Preliminary efficacy and safety data from study in patients with venous leg ulcers and diabetic foot ulcers, from a clinical pharmacology study demonstrating EscharEx's fast and effective debriding activity accompanied with reduction in biofilm and bacterial load.
Lead Product(s): Bromelain Enriched Proteolytic Enzyme
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: EscharEx
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2022
Details:
Patients treated with EscharEx (proteolytic enzymes enriched in bromelain), demonstrated a higher incidence of complete debridement during the 14-day measurement period within up to 8 applications compared to patients treated with gel vehicle.
Lead Product(s): Bromelain Enriched Proteolytic Enzyme
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: EscharEx
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2022
Details:
The study concluded that EscharEx treatment was more effective than the commercially available collagenase agent in removing eschars in this model.
Lead Product(s): Bromelain enriched proteolytic enzymes
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: EscharEx
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2020